Pancreatic cancer (PC), as the leading cause of cancer death worldwide, is one of the deadliest tumors with a very low 5-year survival rate. Therefore, it is urgent to seek new biomarkers of PC for more accurate and reliable treatments. To identify the differentially expressed miRNAs (DEM) in PC tissues, we performed the systematic microarray and qRT-PCR analyses. We found miR-196b was the top dysregulated DEM in PC tissues as compared with the corresponding adjacent tissues, and positively correlated with poor differentiation, tumor size, lymphatic invasion and TNM stage. Furthermore, the late apoptosis rate was significantly reduced, while the cell proliferation was increased in PANC-1 and ASPC-1 cell-lines after treatment with miR-196b mimics. The qRT-PCR and Western blot analysis demonstrated that the level of CADM1 in PANC-1 cells response to the alteration of miR-196b. Moreover, blockade of CADM1 could decrease the late apoptosis in PANC-1 cells as up-regulated by inhibition of miR-196b. Finally, luciferase report assay confirmed that CADM1 was the direct target gene of miR-196b. Overexpression of miR-196b in PC tissues can increase the late apoptosis of pancreatic cancer cells by targeting CADM1. These findings suggested miR-196b is a potential target for diagnosis and therapeutics of human pancreatic cancer.
. Demographic characteristics of 20 PC patients detected in microarray. Data distribution was descripted by median (25 th -75th quarters) for continuous variables and count (percentage) for categorical variables; PC, pancreatic cancer. pancreatic cancer tissues and adjacent tissues was examined by Principal Component Analysis (PCA), and the 3-dimensional PCA (3d-PCA) plot showed that the expression profiles of miRNAs clustered into two separate groups, which was consistent with the source of tissues (Fig. 1A) . In volcano plot, It was demonstrated that 39 miRNAs in pancreatic cancer tissues were significantly down-regulated, and 40 up-regulated compared with adjacent tissues (Fig. 1B , Table S1 ). Next, we identified the common character among these differently expressed miRNAs by enrichment analysis. According to the database of miRNA related diseases, Human microRNA Disease Database 2 (HMDD2), we found that these DEMs were mainly associated with cancers, such as lung neoplasms, and pancreatic neoplasms (Fig. 1C ). Besides, Gene Ontology (GO) annotation was also used to analyze the common functions of these DEMs. Then we found that DEMs focused in and several GO terms associated with cell proliferation, cell apoptosis, and cell death ( Fig. 1D ). Detailed information of enriched terms was presented in Table S2 .
Validation of differentially expressed miRNAs in pancreatic cancer tissues. As shown in Table 2 , we used the 5 top differentially expressed miRNAs (sorted by P value: miR-200c, miR-196b, miR-1, miR-200a, let-7b) in pancreatic cancer tissues compared with adjacent tissues in microarray as candidate miRNAs. In order to validate the difference for the expression level of these miRNAs between pancreatic cancer tissues and adjacent tissues, 80 paired pancreatic and adjacent tissues were examined (20 from the microarray cohort and 60 from the second cohort) with the demographic, clinical and pathological features presented in Table 3 , were used to perform the qRT-PCR assay. Interestingly, we found that the expressions of miR-196b, miR-200a, and miR-200c were up-regulated, but miR-1 was down-regulated in pancreatic cancer tissues compared with adjacent tissues by Wilcoxon signed rank sum test ( Fig. 2 ). However, no statistical difference of let-7b was observed between pancreatic cancer tissues and adjacent tissues. Moreover, miR-196b was observed to be the most significantly differentially expressed one among these miRNAs.
The correlation of miRNA expression and clinicopathological features of PC patients. Next,
we investigated whether the levels of these differentially expressed miRNAs were associated with characteristics of PC patients. As shown in Table 4 , miR-196b was found to be positively associated with poor differentiation, tumor size, lymphatic invasion and higher TNM stage, indicated its critical role in PC progression. In addition, let-7b and miR-200c were demonstrated to be positively correlated with poor differentiation, and miR-200a was positively associated with tumor size, while miR-1 was negatively correlated with poor differentiation.
MiR-196b increased late apoptosis and inhibited cell proliferation of PANC-1 and ASPC-1 cells.
As MiR-196b has been observed to be a candidate biomarker in diagnosis of PC and correlated with clinicopathological features, but the function of miR-196b in PC was still unknown. Therefore, we investigated the function of miR-196b in PC cells by interference experiment. Firstly, we confirmed that the expression of miR-196b was significantly decreased after transfection with miR-196b inhibitor, and was increased after transfection with miR-196b mimics compared with each negative controls ( Fig. 3) . These results were also confirmed in ASPC-1 cells (Fig. S1 ).
Next, we assessed cell apoptosis in PANC-1 cells by two markers, FITC annexin V and propidium iodide (PI). We found that late apoptosis rate was reduced in PANC-1 cells with treatment with miR-196b mimics, and increased with miR-196b inhibitors compared with controls ( Fig. 4A-F) . While there was no significant change has been detected for the early apoptosis rate after transduction of miR-196b mimics or miR-196b inhibitor into PANC-1 cells. We repeat cell apoptosis assay in ASPC-1 cells and found the similar effects of miR-196b on cell apoptosis ( Fig. S2A-F) . Then, We investigated whether miR-196b could regulate proliferation in PANC-1 cells, and found that the percentage of EdU positive cells was decreased in cells transfected with miR-196b inhibitors, while increased after transfected with miR-196b mimics compared with negative controls ( Fig. 5A -E), indicating that miR-196b could facilitate proliferation in PANC-1 cells. The similar results were also found in ASPC-1 cells ( Fig. S3A-E ). Moreover, more percentage of cells was accelerated at G1 phase when treatment with miR-196b inhibitor, and which was decreased after treatment with miR-196b mimics in PANC-1 cells ( Fig. 6A-E ).
MiR-196b down-regulates the expression of CADM1 in PANC-1 and ASPC-1 cells. Using
TargetScan analysis (http://www.targetscan.org/) ( Table 5 ), We found 5 candidate genes (CADM1, HOXA13, IER3, MEF2C, PTGS2) targeting miR-196b. It was demonstrated that only the mRNA level of CADM1 was significantly increased in PANC-1 cells after treatment with miR-196b inhibitor, and was decreased after treatment with miR-196b mimics (Fig. 7A) . These results from ASPC-1 cells confirmed the finding in PANC-1 cells. Furthermore, it suggested that HOXA13 may also response to treatment of miR-196b ( Fig. S4) . Consistently, miR-196b reduced the protein level of CADM1 in PANC-1 cells (Fig. 7B,C) . These results suggested that CADM1 may be a direct target of miR-196b.
MiR-196b inhibited CADM1 expression by binding to its 3′UTR.
To verify that CADM1 was the direct target gene of miR-196b, luciferase report assay was performed. By RNAhybrid software, we confirmed that there are two significant binding sites of miR-196b in 3′UTR of CADM1 ( Fig. 8 ). Then, we constructed two single mutants at each binding site and one double mutant at both binding sites, labeled as MUTA, MUTB and MUTAB in luciferase report system (Fig. 8 ). We found that the luciferase reporter activity of CADM1 was significantly repressed after treatment with miR-196b mimic ( Fig. 9, left panel) . These results suggested that CADM1 was a direct target of miR-196b. Furthermore, we found that only signal from cotransfection of CADM1 with double mutant at both binding sites (MUTAB) had significant changes as compared to WT + miR-196b mimic, while no obvious difference to the WT + NC group (Fig. 9, right panel) . It suggested that both of these two binding sites in 3′UTR of CADM1 were required for the effectively binding between miR-196b and CADM1.
MiR-196b regulated late apoptosis through CADM1 in PANC-1 cells. To find out whether miR-196b
regulated PANC-1 cell apoptosis through CADM1, the loss-of-function experiment for CADM1 by shRNA was performed. As shown in Fig. 10 , transfection of shRNA targeting CADM1 into cells suppressed the expression of CADM1, even in cell with miR-196b inhibitor. It was also demonstrated that miR-196b inhibitor decreased the expression of miR-196b in PANC-1 cells, but blockade of CADM1 did not change the level of miR-196b ( Fig. 10) . Intriguingly, the late apoptosis rate was decreased after transfection of shRNA targeting CADM1, and blockade of CADM1 could decrease the late apoptosis up-regulated by inhibition of miR-196b ( Fig. 11A-E) . These findings indicated that miR-196b regulated PANC-1 cell apoptosis through down-regulation of CADM1.
Discussion
PC has been recognized as one of the most malignant cancers worldwide, as the annual mortality of PC is almost same as the morbidity 5, 6 . Therefore, finding new indicators for helping the diagnosis, treatment, and prognosis of PC, is necessary. Besides, miRNAs have been found to be as tumor suppressors or promoters through regulating the expression of target genes 12 . In our study, we demonstrated that miR-196b expression is significantly up-regulated in PC tissues, positively correlated with differentiation grades and metastasis, and miR-196b regulates apoptosis and proliferation of PANT-1 and ASPC-1 cells via targeting CADM1. According to the position and sequence information of two binding sites, we developed two single mutant and one double mutant of CADM1 3′UTR, whose mutated bases were labeled in red.
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The miR-196 family, including miR-196a and miR-196b, has been reported to be up-regulated in many cancers, such as breast cancer, leukemia, and colonic cancer [16] [17] [18] . Moreover, the level of miR-196b has been demonstrated to be increased in serum of PC patients, but the exact functions of miR-196b in PC was still unknown. In our study, we demonstrated that miR-196b expression was up-regulated in PC tissues compared with adjacent tissues, which was consistent with other cancer tissues and serum of PC patients in previous studies.
Accumulating studies have shown that miRNAs could act as biomarkers for different diseases, especially cancers, and be correlated with clinical characteristics of those patients 10, 12 . In this end, we next questioned whether miR-196b was correlated with characteristics of PC patients. We found miR-196b was positively associated with differentiation grades and metastasis in PC patients. Previous studies have shown that miR-196b could regulate differentiation and migration of gastric cancer cells, which may account for the results in this study 19 . The functions of miR-196b in cancers were also studied, and miR-196b was found to be regulating proliferation, apoptosis, differentiation and migration in different cancer cells [19] [20] [21] . In current study, miR-196b was found to promote proliferation, but inhibit apoptosis of PANC-1 and ASPC-1 cells, which was consistent with the results in other types of cancer cell in previous studies.
Our finding demonstrated that CADM1 was a target gene of miR-196b in PANC-1 cells. CADM1, which is also called as TSCL1, has been reported to be involved in cell adhesion, migration, and apoptosis [22] [23] [24] . Besides, previous study has found that CADM1 expression was down-regulated in different types of cancers, including gastric cancer, breast cancer, and lung carcinoma [25] [26] [27] . In this study, we found that miR-196b could reduce the expression of CADM1 in PANC-1 cells. Furthermore, the late apoptosis rate was decreased after transfection of shRNA targeting CADM1, and blockade of CADM1 could decrease the late apoptosis up-regulated by inhibition of miR-196b. Finally, luciferase assay confirmed that CADM1 was the target gene of miR-196b in PANC-1 cells.
In summary, our data showed that miR-196b expression is up-regulated in PC tissues, and miR-196b regulate apoptosis and proliferation of PANT-1 cells via targeting CADM1. Besides, the level of miR-196b was positively correlated with differentiation grades and metastasis in PC patients. Therefore, miR-196b might be an important biomarker in PC patients.
Methods
Clinical Specimens. Paired cancer tissues and adjacent tissues were obtained from patients recruited at Department of Gastroenterology, Zhongnan Hospital of Wuhan University, from August 2014 to July 2016, and all the patients provided written informed consent before the study protocol, with Ethical Approval provided by Two patient tissue cohorts were used in this study. One cohort consisted of 20 paired cancer tissues and adjacent tissues from patients with PC, which were used for miRNA microarray profiling. The other cohort with 60 paired cancer tissues and adjacent tissues from PC patients was added to the former cohort to further validate the differentially expressed miRNAs in RT-PCR. The demographic characteristics of the two groups of PC patients were described in Table 1 (20 patients) and Table 3 (80 patients). miRNA nanostring analysis. RNA was extracted from tissue samples using TRIzol (Invitrogen, USA), and 100ng total RNA of each samples was used for analysis the expression of miRNAs using NanoString nCounter Human miRNA assay (v1) (NanoString, USA), which contains 654 probes for human miRNAs, according to manufacturer's instructions. Global miRNA array analysis was performed by importing all data into nSolver Analysis Software v1.0 (Nanostring Technologies) and normalized to the geometric mean of the 100 miRNAs with the highest expression values. All analysis was performed using R/Bioconductor, and filtering of low-intensity signals were then conducted by requiring the mean signal intensity for tissue samples to be larger than 500.
3d PCA (Principal Components Analysis) and volcano plot were applied to describe the pattern of miRNA expression between pancreatic cancer tissues and adjacent tissues. R package limma was used to compare miRNA expression between pancreatic cancer tissues and adjacent tissues, and the differentially expressed miRNAs were required to meet criteria (absolute (log (fold change)) >1 and adjust p value < 0.05). Human microRNA Disease Database 2 (HMDD2) and Gene Ontology (GO) annotation were used to identify the relationship of the differentially expressed miRNAs with diseases and functions. The enrichment analysis of differentially expressed miRNAs was competed by R, based on the hypergeometric distribution. the All-in-One ™ miRNA First-Strand cDNA Synthesis Kit (GeneCopoeia), and the miRNA expression was then determined by real-time PCR using the All-in-One ™ miRNA qPCR Kit (GeneCopoeia). As for measurement of the expressions of mRNAs (CADM1 (Sense: TGCTGTGCTTGCTCATCATTCT Anti-sense: TCTGCGTCTGCTGCGTCAT), HOXA13 (Sense: CGCTTCAGAACTCGTTGCTTTG Anti-sense: CGGAAGAACTGGCAGTCTTTACCT), IER3 (Sense: CCAGATCCTGATGGCTGAAGAG Anti-sense: TGAGGTCCAGAGCGTAGTCC) MEF2C (Sense: TCTGTCTGGCTTCAACACTG Anti-sense: TGGTGGTACGGTCTCTAGGA), PTGS2 (Sense: TGACCAGAGCAGGCAGATGA Anti-sense: CCAGTAGGCAGGAGAACATATAACA)), RNA was subjected to reverse transcription with 5 × All-In-One RT MasterMix kit (Applied Biological), and quantitative real-time PCR was conducted using a SYBR Green PCR kit (TaKaRa). miRNA and mRNA expression were evaluated by using the 2 -ΔΔCT method with normalization to internal control, U6 (Sense: CTCGCTTCGGCAGCACA Anti-sense: AACGCTTCACGAATTTGCGT) and β-actin (Sense: ATCATGTTTGAGACCTTCAACA Anti-sense: CATCTCTTGGTCGAAGTCCA), respectively.
Cell culture and transfection. PANC-1 and ASPC-1 cells were cultured in Dulbecco's modified Eagle medium containing 10% FBS, 1% penicillin/streptomycin, and 1% glutamine. Here, 5 nmol/L of miR-196b mimic, 50 nmol/l of miR-196b inhibitor and each negative control (Ambion, Austin, TX) were transfected into PANC-1 by using Lipofectamine RNAiMAX (Life Technologies) according to manufacturer's instructions. The shRNA targeting CADM1 was from position + 1225 to + 1274, relative to the transcription start site, while its negative control did not match any known mammalian genomic sequence.
Cell apoptosis assay. After culture in serum-free medium for 24 hours to induce apoptosis, cells were harvested and stained with FITC annexin V and propidium iodide (PI). Cells fixed by 4% paraformaldehyde for 15 mins were used as positive control for cell apoptosis assay. Subsequently, apoptosis rate was analyzed by cytometry. 
